Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates improved safety and efficacy of convalescent plasma, suggesting future trials are needed.
With pandemic progression, the COVID-19 convalescent plasma safety and efficacy evidence quality increased. Ultimate regulatory approval required robust randomized control efficacy data. Future infectious disease outbreaks require randomized controlled trials in the convalescent plasma roadmap.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: